Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–74
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients 18-74 years of age
Single primary liver transplant from a deceased donor
CellCept plus tacrolimus or cyclosporine from time of transplantation (within 72 hours)
Patients with hepatitis C-positive status may be entered if they have had an intraoperative (back table) biopsy of the transplanted liver or will have a biopsy at the time of randomization. This is not required for patients negative for hepatitis C.
You may not be if
Liver allograft from a living donor or a split liver
Multiple organ transplant
Dialysis therapy for \>14 days from transplantation to randomization
History of malignancy in the last 5 years (except hepatoma or non-melanoma skin cancer)
Previous sirolimus therapy
Clareo Health | Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant
